TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

CV Therapeutics, Inc. Investor Investigation over alleged Unfair Price

  • If you currently hold of CV Therapeutics, Inc. (NASDAQ: CVTX) you have options and you should contact the Shareholders Foundation, Inc. immediately!

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Astellas Pharma Inc. (Astellas) announced on Tuesday, January 27, 2009, a proposed acquisition of CV Therapeutics, Inc. for $16 cash and Gilead Sciences, Inc proposed on March 12, 2009 to acquire CV Therapeutics for $20.00 per share in cash. An investigation on behalf of current investors in CV Therapeutics alleging the transaction appears to be unfair and undervalues the CV Therapeut...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: